ArticleLancet (London, England)2018
Vulnerability to snakebite envenoming: a global mapping of hotspots.
Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 195 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of a Multi-Dose Regimen of Oral Varespladib-Methyl in Subjects Bitten by Venomous Snakes
Mapping Snakebite Risk in Ghana and Rwanda: Using Primary Data Collection and Geostatistical Techniques to Develop an Approach to Risk Estimation for Snakebite
Who cites it
195 citing papers in PubMed, 5 syntheses or guidelines pooled it, 352 citations in OpenAlex.
- First-aid, pre-hospital care, and harmful indigenous practices in pediatric snakebite envenomation: A systematic review of global evidence from 1973 to 2025.PLoS neglected tropical diseases · 2026Pooled it
- Pediatric snakebite in Sub-Saharan Africa: Clinical predictors, outcomes, and gaps in care-A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- Use of snake antivenom in the Region of the Americas: a systematic review.Bulletin of the World Health Organization · 2025Pooled it
- A systematic review of variables associated with snakebite risk in spatial and temporal analyses.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Pooled it
- Assessing knowledge and awareness regarding snakebite and management of snakebite envenoming in healthcare workers and the general population: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2023Pooled it
- A double narrative: stories underpin fearful community attitudes toward snakes but offer a mechanism to reduce human-to-snake conflict.Global health action · 2026Article
- Persistent spatial hotspots and socioeconomic inequalities of snakebite envenoming in Peru: A nationwide spatiotemporal analysis, 2010-2025.PLoS neglected tropical diseases · 2026Article
- Epidemiological characterization of snakebite in Colombia, 2017-2023.Tropical medicine and health · 2026Article
- Estimates of global burden of snakebite: A literature review and geostatistical modelling study.PLoS medicine · 2026Review
- Animal models in venom and antivenom research: The need to align academic discovery with manufacturing and regulatory expectations.PLoS neglected tropical diseases · 2026Review
- A Case ofClinical case reports · 2026Article
- The disease that bites - an assessment of demographics, clinical characteristics, and treatment practices of patients with snakebite envenoming across Vietnam.Journal of global health · 2026Article
- The cobras (genus Naja) of Myanmar: An updated species list with information on identification, distributions, and medical importance.PLoS neglected tropical diseases · 2026Article
- A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies.ACS pharmacology & translational science · 2026Review
- Climate change induced complex shifts in snake distributions expose people to snakebite and threaten biodiversity.PLoS neglected tropical diseases · 2026Article
- Article
- Look what you make my tissues do: The role of metalloproteinases and their inhibitors in Bothrops snakebites.PLoS neglected tropical diseases · 2026Article
- Preclinical evidence of adenosine for early intervention in Bungarus multicinctus envenomation.Journal of advanced research · 2026Article
- Toxicological profiling of venoms from ten major Chinese snakes: a mass spectrometry-based proteomic and multiroute assessment.Archives of toxicology · 2026Article
- The burden of diseases from human-animal contact in 2021: a spatiotemporal analysis using the "Production-Living-Ecology" framework.BMC global and public health · 2026Article
135 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundSnakebite envenoming is a frequently overlooked cause of mortality and morbidity. Data for snake ecology and existing snakebite interventions are scarce, limiting accurate burden estimation initiatives. Low global awareness stunts new interventions, adequate health resources, and available health care. Therefore, we aimed to synthesise currently available data to identify the most vulnerable populations at risk of snakebite, and where additional data to manage this global problem are needed.
methodsWe assembled a list of snake species using WHO guidelines. Where relevant, we obtained expert opinion range (EOR) maps from WHO or the Clinical Toxinology Resources. We also obtained occurrence data for each snake species from a variety of websites, such as VertNet and iNaturalist, using the spocc R package (version 0.7.0). We removed duplicate occurrence data and categorised snakes into three groups: group A (no available EOR map or species occurrence records), group B (EOR map but <5 species occurrence records), and group C (EOR map and ≥5 species occurrence records). For group C species, we did a multivariate environmental similarity analysis using the 2008 WHO EOR maps and newly available evidence. Using these data and the EOR maps, we produced contemporary range maps for medically important venomous snake species at a 5 × 5 km resolution. We subsequently triangulated these data with three health system metrics (antivenom availability, accessibility to urban centres, and the Healthcare Access and Quality [HAQ] Index) to identify the populations most vulnerable to snakebite morbidity and mortality.
findingsWe provide a map showing the ranges of 278 snake species globally. Although about 6·85 billion people worldwide live within range of areas inhabited by snakes, about 146·70 million live within remote areas lacking quality health-care provisioning. Comparing opposite ends of the HAQ Index, 272·91 million individuals (65·25%) of the population within the lowest decile are at risk of exposure to any snake for which no effective therapy exists compared with 519·46 million individuals (27·79%) within the highest HAQ Index decile, showing a disproportionate coverage in reported antivenom availability. Antivenoms were available for 119 (43%) of 278 snake species evaluated by WHO, while globally 750·19 million (10·95%) of those living within snake ranges live more than 1 h from population centres. In total, we identify about 92·66 million people living within these vulnerable geographies, including many sub-Saharan countries, Indonesia, and other parts of southeast Asia.
interpretationIdentifying exact populations vulnerable to the most severe outcomes of snakebite envenoming at a subnational level is important for prioritising new data collection and collation, reinforcing envenoming treatment, existing health-care systems, and deploying currently available and future interventions. These maps can guide future research efforts on snakebite envenoming from both ecological and public health perspectives and better target future estimates of the burden of this neglected tropical disease.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.